264 related articles for article (PubMed ID: 8925538)
21. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
[TBL] [Abstract][Full Text] [Related]
22. [Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination].
Zeman M; Zák A; Vecka M; Tvrzická E; Písaríková A; Stanková B
Cas Lek Cesk; 2005; 144(11):737-41. PubMed ID: 16335699
[TBL] [Abstract][Full Text] [Related]
23. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
[TBL] [Abstract][Full Text] [Related]
24. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
Lehtonen A; Viikari J
Artery; 1982; 10(5):353-67. PubMed ID: 7181678
[TBL] [Abstract][Full Text] [Related]
25. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
Arca M; Montali A; Pigna G; Antonini R; Antonini TM; Luigi P; Fraioli A; Mastrantoni M; Maddaloni M; Letizia C
Metabolism; 2007 Nov; 56(11):1534-41. PubMed ID: 17950105
[TBL] [Abstract][Full Text] [Related]
26. Ezetimibe treatment of pediatric patients with hypercholesterolemia.
Clauss S; Wai KM; Kavey RE; Kuehl K
J Pediatr; 2009 Jun; 154(6):869-72. PubMed ID: 19230898
[TBL] [Abstract][Full Text] [Related]
27. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.
Ruel IL; Lamarche B; Mauger JF; Badellino KO; Cohn JS; Marcil M; Couture P
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2600-7. PubMed ID: 16224048
[TBL] [Abstract][Full Text] [Related]
28. [Personal experience with 200mg of micronized fenofibrate (Lipanthyl 200 M) in the treatment of primary dyslipidemias].
Vaverková H; Novotný D; Ficker L
Vnitr Lek; 1996 Apr; 42(4):239-45. PubMed ID: 8693709
[TBL] [Abstract][Full Text] [Related]
29. Effect of fenofibrate on serum lipoproteins in subjects with familial hypercholesterolemia and combined hyperlipidemia.
Weisweiler P; Merk W; Janetschek P; Schwandt P
Atherosclerosis; 1984 Dec; 53(3):321-5. PubMed ID: 6529448
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of familial hypercholesterolemia using Mevacor. Initial experience].
Ceska R; Sobra J; Procházková R; Kvasilová M
Cas Lek Cesk; 1989 May; 128(21):661-3. PubMed ID: 2758454
[TBL] [Abstract][Full Text] [Related]
31. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
Alrasadi K; Awan Z; Alwaili K; Ruel I; Hafiane A; Krimbou L; Genest J
Am J Cardiol; 2008 Nov; 102(10):1341-7. PubMed ID: 18993152
[TBL] [Abstract][Full Text] [Related]
32. [Etophylline clofibrate in the treatment of familial combined hyperlipoproteinemia].
Raslová K; Hucková M
Vnitr Lek; 1995 Apr; 41(4):240-2. PubMed ID: 7762188
[TBL] [Abstract][Full Text] [Related]
33. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Branchi A; Rovellini A; Sommariva D; Gugliandolo AG; Fasoli A
Thromb Haemost; 1993 Aug; 70(2):241-3. PubMed ID: 8236126
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Bruckert E; De Gennes JL; Malbecq W; Baigts F
Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
[TBL] [Abstract][Full Text] [Related]
35. The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia.
Koter M; Broncel M; Chojnowska-Jezierska J; Klikczynska K; Franiak I
Eur J Clin Pharmacol; 2002 Nov; 58(8):501-6. PubMed ID: 12451426
[TBL] [Abstract][Full Text] [Related]
36. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
Farnier M; Freeman MW; Macdonell G; Perevozskaya I; Davies MJ; Mitchel YB; Gumbiner B;
Eur Heart J; 2005 May; 26(9):897-905. PubMed ID: 15781429
[TBL] [Abstract][Full Text] [Related]
38. [level of 7alpha-hydroxycholesterol in blood plasma as an indicator of cholesterol catabolism in hyperlipidemia and with hypolipidemic therapy].
Poliakova ED; Ivanova TN; Voshchinnikov EI; Olfer'ev AM; Perova NV
Vopr Med Khim; 2000; 46(2):168-75. PubMed ID: 10885038
[TBL] [Abstract][Full Text] [Related]
39. Effect of procetofen on serum lipids and apoproteins.
Capurso A; Mogavero AM; Taverniti R; Resta F; Pace L; Bonomo L
Int J Clin Pharmacol Ther Toxicol; 1984 Apr; 22(4):194-7. PubMed ID: 6715088
[TBL] [Abstract][Full Text] [Related]
40. [Lipid, apoprotein and fibrinogen levels in the blood of male patients following myocardial infarct and the effect of diet on these parameters in ischemic heart disease].
Márk L; Wolf I; Kántor M; Lestyán K; Orosz I
Orv Hetil; 1996 Nov; 137(44):2447-50. PubMed ID: 9026757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
